AU2015317741B2 - MK2 inhibitors and uses thereof - Google Patents

MK2 inhibitors and uses thereof Download PDF

Info

Publication number
AU2015317741B2
AU2015317741B2 AU2015317741A AU2015317741A AU2015317741B2 AU 2015317741 B2 AU2015317741 B2 AU 2015317741B2 AU 2015317741 A AU2015317741 A AU 2015317741A AU 2015317741 A AU2015317741 A AU 2015317741A AU 2015317741 B2 AU2015317741 B2 AU 2015317741B2
Authority
AU
Australia
Prior art keywords
aliphatic
compound
optionally substituted
nitrogen
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015317741A
Other languages
English (en)
Other versions
AU2015317741A1 (en
Inventor
Matthew David Alexander
Claudio Chuaqui
John MALONA
Joseph John MCDONALD
Guobin MIAO
Yike Ni
Deqiang Niu
Chittari Pabba
Russell C. Petter
Juswinder Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2015317741A1 publication Critical patent/AU2015317741A1/en
Application granted granted Critical
Publication of AU2015317741B2 publication Critical patent/AU2015317741B2/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY Request for Assignment Assignors: CELGENE CAR LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2015317741A 2014-09-17 2015-09-16 MK2 inhibitors and uses thereof Active AU2015317741B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US62/051,788 2014-09-17
US201562199927P 2015-07-31 2015-07-31
US62/199,927 2015-07-31
PCT/US2015/050495 WO2016044463A2 (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
AU2015317741A1 AU2015317741A1 (en) 2017-04-20
AU2015317741B2 true AU2015317741B2 (en) 2020-01-16

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015317741A Active AU2015317741B2 (en) 2014-09-17 2015-09-16 MK2 inhibitors and uses thereof

Country Status (30)

Country Link
US (5) US9458175B2 (pt-PT)
EP (2) EP3193611B1 (pt-PT)
JP (3) JP6556225B2 (pt-PT)
KR (1) KR102457848B1 (pt-PT)
CN (1) CN106998692B (pt-PT)
AU (1) AU2015317741B2 (pt-PT)
BR (1) BR112017005266B1 (pt-PT)
CA (1) CA2961607C (pt-PT)
CL (1) CL2017000576A1 (pt-PT)
CO (1) CO2017003279A2 (pt-PT)
CY (1) CY1124215T1 (pt-PT)
DK (1) DK3193611T3 (pt-PT)
EA (1) EA037299B1 (pt-PT)
EC (1) ECSP17023281A (pt-PT)
ES (1) ES2874561T3 (pt-PT)
HR (1) HRP20210529T1 (pt-PT)
HU (1) HUE054347T2 (pt-PT)
IL (1) IL251051B (pt-PT)
LT (1) LT3193611T (pt-PT)
MA (1) MA40534B1 (pt-PT)
MX (2) MX2017003359A (pt-PT)
NZ (1) NZ730603A (pt-PT)
PL (1) PL3193611T3 (pt-PT)
PT (1) PT3193611T (pt-PT)
RS (1) RS62017B1 (pt-PT)
SA (1) SA517381115B1 (pt-PT)
SG (2) SG11201701861RA (pt-PT)
SI (1) SI3193611T1 (pt-PT)
TW (1) TWI744217B (pt-PT)
WO (1) WO2016044463A2 (pt-PT)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105163738A (zh) 2013-03-15 2015-12-16 西建阿维拉米斯研究公司 Mk2抑制剂和其用途
EP3193611B1 (en) 2014-09-17 2021-03-24 Celgene Car Llc Mk2 inhibitors and uses thereof
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
JP7200120B2 (ja) * 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
MX2019010643A (es) * 2017-03-16 2019-10-17 Celgene Car Llc Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
EP3596085A4 (en) * 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2018170204A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
KR20220041042A (ko) * 2019-05-17 2022-03-31 셀젠 카르 엘엘씨 Mk2-매개 장애를 치료하는 방법
WO2021163633A1 (en) * 2020-02-14 2021-08-19 Salk Institute For Biological Studies Mono and combination therapies with ulk1/2 inhibitors
EP4114411A4 (en) * 2020-03-02 2024-04-24 Washington University COMPOSITIONS AND METHODS FOR THE TREATMENT OF PANCREATIC CANCER
JP2023536427A (ja) * 2020-07-24 2023-08-25 ブリストル－マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
CN117940433A (zh) * 2021-08-27 2024-04-26 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
RU2005119173A (ru) 2002-12-20 2006-02-27 Фармация Корпорейшн (Us) Ациклические пиразольные соединения
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
WO2006084186A2 (en) 2005-02-04 2006-08-10 Senomyx, Inc. Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2008277676A1 (en) 2007-07-16 2009-01-22 Novartis Ag Heterocyclic compounds useful as MK2 inhibitors
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2817388B1 (en) 2012-02-22 2020-03-25 Merck Patent GmbH Liquid crystalline medium
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
SG11201502184VA (en) * 2012-09-24 2015-04-29 Claremont Speede Mobile sender controlled data access and data deletion method and system
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CN105163738A (zh) * 2013-03-15 2015-12-16 西建阿维拉米斯研究公司 Mk2抑制剂和其用途
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
WO2016032882A1 (en) 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
EP3193611B1 (en) 2014-09-17 2021-03-24 Celgene Car Llc Mk2 inhibitors and uses thereof
RU2017128077A (ru) 2015-01-08 2019-02-08 Мори Матрикс, Инк. Составы, содержащие пептиды, ингибирующие мк2
MX2019010643A (es) 2017-03-16 2019-10-17 Celgene Car Llc Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
WO2018170204A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
KR20220041042A (ko) 2019-05-17 2022-03-31 셀젠 카르 엘엘씨 Mk2-매개 장애를 치료하는 방법
JP2023536427A (ja) 2020-07-24 2023-08-25 ブリストル－マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SENTHIL NATESAN ET AL, JOURNAL OF MEDICINAL CHEMISTRY, (2012-03-08), vol. 55, no. 5, , pages 2035 - 2047 *

Also Published As

Publication number Publication date
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
US20210053984A1 (en) 2021-02-25
US9458175B2 (en) 2016-10-04
KR20170063734A (ko) 2017-06-08
MA40534A (fr) 2016-03-24
US20190375762A1 (en) 2019-12-12
EP3193611B1 (en) 2021-03-24
TW201617351A (zh) 2016-05-16
US10253040B1 (en) 2019-04-09
JP6556225B2 (ja) 2019-08-07
EA037299B1 (ru) 2021-03-05
JP2017529367A (ja) 2017-10-05
US9790235B2 (en) 2017-10-17
LT3193611T (lt) 2021-08-25
CO2017003279A2 (es) 2017-09-29
WO2016044463A2 (en) 2016-03-24
KR102457848B1 (ko) 2022-10-25
CL2017000576A1 (es) 2017-12-01
CN106998692A (zh) 2017-08-01
EP3193611A4 (en) 2018-02-28
US10577380B2 (en) 2020-03-03
US20170114073A1 (en) 2017-04-27
SA517381115B1 (ar) 2021-03-09
SI3193611T1 (sl) 2021-08-31
CN106998692B (zh) 2020-09-08
JP2019194236A (ja) 2019-11-07
US11584757B2 (en) 2023-02-21
EP3193611A2 (en) 2017-07-26
DK3193611T3 (da) 2021-05-10
JP7375072B2 (ja) 2023-11-07
CA2961607A1 (en) 2016-03-24
BR112017005266A2 (pt) 2017-12-12
NZ730603A (en) 2024-02-23
IL251051A0 (en) 2017-04-30
MA40534B1 (fr) 2021-04-30
SG11201701861RA (en) 2017-04-27
IL251051B (en) 2019-11-28
SG10201902326XA (en) 2019-04-29
BR112017005266B1 (pt) 2022-11-01
CA2961607C (en) 2023-03-28
MX2020005213A (es) 2020-08-20
EP3912981A1 (en) 2021-11-24
HUE054347T2 (hu) 2021-08-30
RS62017B1 (sr) 2021-07-30
PL3193611T3 (pl) 2021-10-04
US20160075720A1 (en) 2016-03-17
ECSP17023281A (es) 2017-06-30
EA201790380A1 (ru) 2017-08-31
PT3193611T (pt) 2021-05-28
CY1124215T1 (el) 2022-05-27
AU2015317741A1 (en) 2017-04-20
MX2017003359A (es) 2017-11-22
JP2022078315A (ja) 2022-05-24
WO2016044463A3 (en) 2016-09-01
TWI744217B (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
AU2015317741B2 (en) MK2 inhibitors and uses thereof
JP6554507B2 (ja) ヘテロアリール化合物およびそれらの使用
CA2900748C (en) Novel pyrimidine and pyridine compounds and their usage
EP3813819A1 (en) Inhibitors of cyclin-dependent kinases
CN114502536A (zh) 作为激酶抑制剂的杂环化合物
CN112638910B (zh) 新的杂环胺衍生物及包含其的药物组合物
WO2016090079A1 (en) Heteroaryl compounds and uses thereof
JP7213193B2 (ja) Ｎｉｋ阻害剤としての新規の置換アザインドリン誘導体
KR20190026917A (ko) 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
JP2023540548A (ja) 抗腫瘍活性を有する化合物及びその使用
WO2022237858A1 (zh) 一种具有抗肿瘤活性的化合物及其用途
KR20210108433A (ko) 티에노피리디논 화합물
WO2024092115A2 (en) Mk2 inhibitors and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTORS TO ADD MIAO, GUOBIN

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ALEXANDER, MATTHEW DAVID; CHUAQUI, CLAUDIO; MALONA, JOHN; MCDONALD, JOSEPH JOHN; NI, YIKE; NIU, DEQIANG; PETTER, RUSSELL C.; SINGH, JUSWINDER; PABBA, CHITTARI AND MIAO, GUOBIN

PC Assignment registered

Owner name: BRISTOL-MYERS SQUIBB COMPANY

Free format text: FORMER OWNER(S): CELGENE CAR LLC